Trials

Question 1

This trial demonstrated no benefit and increased stroke risk for routine aspiration thrombectomy during PCI for STEMI

Answer 1

TOTAL (NEJM 2015)

Question 2

This trial demonstrated continuing warfarin through ICD/PPM implantation decreased pocket hematoma incidence compared to bridging with heparin

Answer 2

BRUISE CONTROL (NEJM 2013)

Question 3

Which statin is associated with decreased GFR and increased proteinuria and what trial showed that?

Answer 3

Rosuvastatin
PLANET trial

Question 4

Anakinra MOA and trial for recurrent pericarditis

Answer 4

IL1-beta receptor antagonist
AIRTRIP (JAMA, 2016)

Question 5

Rilonacept MOA and trial for recurrent pericarditis

Answer 5

IL1-alpha and IL1-beta cytokine trap
RHAPSODY (NEJM, 2021)

Question 6

This trial showed no benefit for pre-hospital ticagrelor vs in-cath lab ticagrelor for STEMI

Answer 6

ATLANTIC (NEJM, 2014)

Question 7

This trial showed dronedarone reduced composite 1* outcome CV hospitalization + death in patients with AF

Answer 7

ATHENA (NEJM, 2009)

Question 8

Trial showing benefit of continuing GDMT in HFimpEF

Answer 8

TRED-HF
(Lancet 2019)

Question 9

Omecamtiv mecarbil (cardiac myosin activator) phase III RCTs

Answer 9

GALACTIC-HF (NEJM 2020): OM reduced composite of HHF + CV death

METEORIC-HF (JAMA 2022): OM did not improve exercise capacity

Question 10

What trial showed target resting HR <80 is noninferior to <110bpm in permanent AF

Answer 10

RACE II (NEJM, 2010)

Question 11

This trial showed dronedarone led to increased mortality and worsening HF in hospitalized HFrEF patients

Answer 11

ANDROMEDA
(NEJM, 2008)

Question 12

This trial showed rivaroxaban 2.5mg BID + ASA reduced MACE but increased major bleeding compared to ASA alone for patients with stable CAD and/or PAD.

Answer 12

COMPASS
(NEJM 2017)

MACE HR 0.76
Bleed HR 1.7

Question 13

This trial showed that in symptomatic HF w/ EF >45% and BMI >30, semaglutide improved QoL (KCCQ) and led to 11% weight loss

Answer 13

STEP-HFpEF
(NEJM, 2023)

Question 14

When these two countries were removed from TOPCAT analysis, the study became + for spiro leading to reduced HHF in HFpEF

Answer 14

Russia + Georgia

(TOPCAT-Americas, Circ 2015)

Question 15

This trial showed finerenone reduced composite of CVD + WHF in symptomatic HF patients with LVEF >40%

Answer 15

FINEARTS-HF
(NEJM, 2024)

Question 16

This trial showed that in MI w/ LVEF >50%, beta-blockers did NOT reduce composite of ACM or new MI

Answer 16

REDUCE-AMI
(NEJM, 2024)

Question 17

This trial showed that in patients w/ BMI >27 and ASCVD without T2DM, semaglutide reduced MACE

Answer 17

SELECT
(NEJM, 2023)

Question 18

This trial showed that in symptomatic HF LVEF >45%, sac-val did NOT improve a composite of HHF + CVD

Answer 18

PARAGON-HF
(NEJM, 2019)

Question 19

This trial showed in symptomatic HF EF >40%, empagliflozin reduced a composite of time to 1st HHF or CVD (CVD non-sig)

Answer 19

EMPORER-Preserved
(NEJM, 2021)

Question 20

This trial showed in AF/AFL, apixaban improved mortality, bleeding, and stroke rates vs warfarin

Answer 20

ARISTOTLE
(NEJM, 2011)

Question 21

This trial showed in AF, rivaroxaban is non-inferior to warfarin for bleeding and stroke

Answer 21

ROCKET-AF
(NEJM, 2011)

Question 22

This trial showed in AF, dabigatran 150mg led to lower stroke rate and similar bleeding vs warfarin

Answer 22

RE-LY
(NEJM 2010)

Dabigatran 110mg did not reduce strokes vs warfarin

Question 23

This trial showed in ACS, ticagrelor reduced a composite of CVD, MI, or stroke compared to clopidogrel

Answer 23

PLATO
(NEJM 2009)

Question 24

This trial showed in NSTEMI pre-treating with prasugrel did not improve a MACE composite vs prasugrel at the time of PCI

Answer 24

ACCOAST
(NEJM, 2013)

Question 25

This trial showed in UA/NSTEMI treated medically, prasugrel did NOT improve MACE compared to clopidogrel

Answer 25

TRILOGY-ACS (NEJM, 2012)

Question 26

This trial showed that in UA/NSTEMI undergoing PCI, prasugrel reduced MACE but increased bleeding vs clopidogrel

Answer 26

TRITON-TIMI-38 (NEJM 2007)

Question 27

This trial showed that in UA/NSTEMI, clopidogrel reduced MACE vs placebo

Answer 27

CURE (NEJM 2001)

Question 28

This trial showed that in AF + stable CAD (ie, PCI or CABG >1yr ago), rivaroxaban monotherapy was non-inferior to rivarox+ASA for MACE and trial stopped early for increased bleeding in combo arm

Answer 28

AFIRE (NEJM 2019)

Question 29

This trial showed enalapril in HFrEF w/ class IV sx lowered ACM vs placebo

Answer 29

CONSENSUS (NEJM, 1987)

Question 30

This trial showed metoprolol succinate in symptomatic HFrEF lowered mortality and HHF vs placebo

Answer 30

MERIT-HF (JAMA, 2000)

Question 31

This trial showed in symptomatic HF EF <25%, carvedilol reduced ACM + HHF vs placebo

Answer 31

COPERNICUS (Circ 2002)

Question 32

This trial showed that in AMI with LVEF <40% but without CHF sx, captopril reduced ACM by 19% (NNT = 20) vs placebo.

Answer 32

SAVE (NEJM 1992)

Question 33

This trial showed that in AMI with NYHA II-III CHF sx, ramipril reduced ACM by 27% vs placebo.

Answer 33

AIRE (Lancet 1993)`

Question 34

This trial showed that in AMI with LVEF <40%, carvedilol did not significantly reduce ACM or CV hospitalizations vs placebo

Answer 34

CAPRICORN (Lancet 2001)

Question 35

This trial showed that in AMI, IV followed by oral metoprolol for 15 days did not reduce MACE or death compared to placebo.

Answer 35

COMMIT (Lancet 2005)

Question 36

This trial showed that in AMI with LVEF <35%, trandolapril (ACEi) reduced ACM by 22% (NNT 14) vs placebo.

Answer 36

TRACE (NEJM 1995)

Question 37

This trial showed that in AMI with LVEF <40%, eplerenone decreased ACM by 15% vs placebo.

Answer 37

EPHESUS (NEJM 2003)

Question 39

This trial showed that in patients with left main disease low/intermediate SYNTAX score (<33), PCI was non-inferior to CABG for MACE (stroke, MI, death) at 3 years

Answer 39

EXCEL (NEJM 2016)

Question 40

This trial showed that IVUS-guided (vs angiography alone) PCI in ACS decreased target vessel failure by 65% at 12 months.

Answer 40

ULTIMATE (JACC 2018)

Question 41

This trial showed that OCT-guided (vs angio-guided) PCI of bifurcation lesions led to lower MACE.

Answer 41

OCTOBER (NEJM 2023)

Question 42

This trial showed that alirocumab 75mg q14d (vs placebo) in patients w/ MI w/in 12 mo on statin w/ residual LDL >70 decreased MACE by 15% (also decreased ACM by 15%).

Answer 42

ODYSSEY OUTCOMES (NEJM 2018)

Question 43

This 2x2 factorial trial showed that in patients with acute MI, (1) Colchicine did not improve MACE (2) Spironolactone did not improve MACE or WHF

Answer 43

CLEAR (NEJM 2025)